Anlon Healthcare IPO GMP Holds Steady at 5% Amid Strong Subscription
Anlon Healthcare’s ₹121 crore initial public offering has attracted strong demand from investors as the issue nears closure. While subscription levels continue to rise, the grey market premium (GMP) is holding steady, signaling moderate listing expectations.
Subscription Snapshot
The IPO has been subscribed around 3.8 times overall, with retail investors leading the demand at nearly 26 times their quota. Non-Institutional Investors (NIIs) subscribed more than twice their portion, while Qualified Institutional Buyers (QIBs) participation also picked up steadily.
GMP Insight
The Anlon Healthcare IPO GMP is currently at ₹5, which suggests a likely listing price of about ₹96 per share, compared to the upper price band of ₹91. This indicates a potential 5–6% listing gain if current trends continue.
What It Means for Investors
The strong response from retail investors highlights growing confidence in Anlon Healthcare’s growth story. However, the steady Anlon Healthcare IPO GMP reflects that while investors expect positive listing gains, they are likely to be modest rather than sharp.
The company’s presence in the pharmaceutical ingredients and intermediates space, along with its focus on research-driven products, positions it well in a growing market. At the same time, investors must weigh risks such as regulatory challenges, dependence on a single manufacturing facility, and global competition.
Risk Disclaimer
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investors should consult a professional advisor before investing. Grey Market Premium (GMP) is an unofficial indicator and can be volatile exercise caution when assessing expected listing gains.
